Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Economics and health are interlinked in many ways, as seen in the vicious cycle between poverty and ill health. Merging data from various research areas within economic models allows a more efficient use of scarce resources. Economic evaluation helps ensure that cost effective interventions are included in policy recommendations.

Q: What is the link between economics and how we understand and treat diseases?

Yoel Lubell: Economics and health are interlinked in many ways. One example is the vicious cycle we see between poverty and ill health, which is true at the patient level and for households, but it is also true for countries. You may see associations between malaria transmission and slower GDP growth for instance. My own research focuses more on economic evaluation of new interventions. For example, if we have a new diagnostic test for malaria, I would be looking at how beneficial it is, what the health gains are, what the costs are, and then try and put those together and say whether or not this is an efficient use of inevitably scarce resources.

Q: What has your research found?

YL: We have looked at diagnostics for malaria and treatments for malaria. We have identified some of these which are very efficient and very cost effective. I would like to think that it was somewhat informative in a lot of the policy making over the past few years, in terms of moving from treating all fevers as malaria to requiring that all fevers are tested for malaria before patients receive treatment. That has been one potential contribution to global health.

Q: Have you found it has changed the way in which we understand diseases such as malaria?

YL: The work I do is not normally lab based, looking at things like parasites. But I think it has been very informative in how we manage malaria, so that we now treat fevers as a whole. It is very important to diagnose and treat malaria which can be a deadly disease, but we have really highlighted with a lot of modelling the importance of considering the benefits and the health gains that could be obtained by better management of what we call the non-malarial fevers.

What I have been doing more recently is trying to identify potential tests that could be used to try and direct the use of antibiotics within these non-malarial fevers. We have identified bio-markers that could be very effective at this and we are moving towards developing simple tests that could be used by relatively untrained community health workers to say 'now that I know that this patient does not have malaria, do they require an antibiotic or not?'

Q: What are they most important lines of research which have emerged over the past 5-10 years?

YL: When I started approximately 10 years ago, very advanced methodologies were being used in high income settings to evaluate new interventions, while things were much more basic for malaria and other tropical diseases. I was very lucky that I got my PhD just by applying relatively simple methods that were being used routinely, to malaria, an area they had almost never been applied before. What we have seen over the past decade or so is that the field is catching up: now in our own research units for instance, we are focusing on merging transmission dynamic models, where we try and do some kind of projection for how diseases are transmitted, with economic models where we can have economic inputs and outputs. Again, this is to estimate what the most cost effective of combinations of interventions are, to try and impact on transmission.

Q: Why is your research important? Why should we fund it?

YL: The main value of doing these economic models is that it seems to be the final point before the research goes out to policy making and we bring together evidence from many different fields: epidemiology, data from clinical trials, social sciences. They all come together in economic models, along with costs as well, to say: given what we know from all of these different areas and given the resource constraints, what would we advise policy makers to actually invest in.

Q: How does your research fit within transitional medicine, within the department?

YL: The focus of economic evaluation is very much on that 'hands-on', 'what is going on', in the field, in routine care, and how we can improve on that with whatever new interventions are being developed. It is not only looking at new interventions once they are developed: economic evaluation can also inform what interventions we should be looking for, even if they don't exist yet. It is what we call the value of information. We can look at what the uncertainties are, where we might invest more in research, in order to reduce uncertainties or to develop new interventions that could have the greatest impact on public health.

Yoel Lubell

Economic Modelling

Dr Yoel Lubell leads the economic team at the MORU Mathematical and Economic Modelling Group, based in Bangkok, Thailand. His research focuses on the evaluation of diagnostics, treatments and vaccines for infectious diseases, with the aim of providing guidance on malaria elimination and control of artemisinin resistance in the Mekong region.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.